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Abstract 
Background: Metastases are the most common reason of cancer death in patients with solid tumors. Lymph nodes, 
once invaded by tumor cells, act as reservoirs before cancer cells spread to distant organs. To address the limited 
access of intravenously infused chemotherapeutics to the lymph nodes, we have developed PEGylated polyglutamic 
acid nanocapsules (PGA‑PEG NCs), which have shown ability to reach and to accumulate in the lymphatic nodes and 
could therefore act as nanotransporters. Once in the lymphatics, the idea is that these nanocapsules would selectively 
interact with cancer cells, while avoiding non‑specific interactions with immune cells and the appearance of subse‑
quent immunotoxicity.
Results: The potential of the PGA‑PEG NCs, with a mean size of 100 nm and a negative zeta potential, to selectively 
reach metastatic cancer cells, has been explored in a novel 3D model that mimics an infiltrated lymph node. Our 3D 
model, a co‑culture of cancer cells and lymphocytes, allows performing experiments under dynamic conditions that 
simulate the lymphatic flow. After perfusion of the nanocarriers, we observe a selective interaction with the tumor 
cells. Efficacy studies manifest the need to develop specific therapies addressed to treat metastatic cells that can be in 
a dormant state.
Conclusions: We provide evidence of the ability of PGA‑PEG NCs to selectively interact with the tumor cells in pres‑
ence of lymphocytes, highlighting their potential in cancer therapeutics. We also state the importance of designing 
precise in vitro models that allow performing mechanistic assays, to efficiently develop and evaluate specific thera‑
pies to confront the formation of metastasis.
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Background
In many types of metastatic cancer, such as lung cancer, 
the regional lymph nodes act as mediators of cancer cells 
leading to distant organ metastases [1]. Unfortunately, 
the lymphatic system is not easily accessible by conven-
tional intravenous infusion of chemotherapeutics due to 
their specific anatomical and physiological characteristics 
[2]. Therefore, eradicating cancer cells that are infiltrated 
in lymph nodes requires the development of specific ther-
apeutic interventions to stop the process of metastases. 
In the last decades, a variety of novel chemotherapeu-
tic agents have lead to major clinical advances, however 
many of them also impact immune cells, suppressing 
cell-mediated innate and adaptive antitumor immunity 
[3]. Recent data revealed that certain chemotherapeutic 
agents affect maturation, cytokine production and T cell 
stimulatory capacity of dendritic cells (DCs), which play 
a crucial role in the induction of antitumor immunity [4, 
5]. For this reason, it is necessary to develop novel thera-
peutic targeted strategies to successfully improve the 
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accessibility and selectivity of anticancer drugs to tumor 
cells allocated in the lymph nodes, avoiding their interac-
tion with immune cells. Within this frame, nanotechnol-
ogy offers interesting opportunities for lymphatic delivery 
[6–8]. At present it is known that particle size, surface 
charge, as well as hydrophilicity, are important param-
eters that can be modulated in order to enhance the abil-
ity of nanocarriers to reach the lymph nodes [9–11]. On 
these premises, we have developed PEGylated polyglu-
tamic acid nanocapsules (PGA-PEG NCs) that exhibit 
several attractive features for an enhanced delivery of 
antitumor drugs to lymph node-resident metastatic cells, 
such as (1) small particle size (close to 100 nm), negative 
zeta potential and hydrophilic surface, and (2) ability to 
encapsulate and release anticancer drugs such as doc-
etaxel. Considering this, and as a step further, we decided 
to study the efficacy and specificity of PGA-PEG NCs 
to interact with disseminated tumor cells in presence of 
immune cells. For that purpose, we focused our efforts in 
the development of a 3D cell culture model mimicking a 
metastatic lymph node that can be perfused with the pro-
posed nanocarriers.
The use of 3D in  vitro systems in drug research and 
development has been suggested as a potential link to 
bridge the gap between monolayer cultures and animal 
studies [12]. 3D models contribute to the design of spe-
cific assays to understand the mode of action of novel 
therapeutic agents [13, 14]. Different approaches have 
focused on the recreation of the microenvironment of the 
lymph nodes for a variety of applications, as for example 
to study the influence of the dynamic flow in structural 
remodeling and production of cytokines [15], to under-
stand immunological interactions [16], or to develop arti-
ficial organs for transplantation [17, 18]. However, to the 
best of our knowledge, the development of a 3D model 
that represents the lymph nodes as metastatic entities 
infiltrated by tumor cells, allowing the perfusion of drugs 
and nanoparticles as novel therapeutic approaches, has 
not been addressed so far.
In this study we present the preparation and charac-
terization of fluorescent PGA-PEG NCs, and explore 
their interaction with cancer cells in a specifically 
designed novel 3D model of a tumor-infiltrated lymph 
node, to determine their potential for the treatment of 
advanced metastatic cancer that undergoes lymphatic 
dissemination.
Methods
Preparation and characterization of DiD‑loaded PGA‑PEG 
NCs
PEGylated Polyglutamic Acid nanocapsules (PGA-PEG 
NCs) were prepared by the solvent displacement tech-
nique. Briefly, the organic phase, composed by 400 µl of 
ethanol, 200  µl of Epikuron 145  V (Cargill, Spain) dis-
solved in ethanol (C = 37.5 mg/ml), 100 µl of hexadecyl-
trimethylammonium bromide (CTAB) (Sigma-Aldrich) 
dissolved in ethanol (C = 15 mg/ml), 31.25 µl of Miglyol 
812® (Sasol Germany GmbH, Germany), and 9.5  ml of 
acetone, was added in aliquots of 250 µl every 15 s over 
an aqueous solution of methoxy-poly(ethylene glycol)-
block-poly(l-glutamic acid sodium salt) (PGA-PEG Mw 
35 kDa, Alamanda Polymers, USA) (C = 0.25 mg/ml in 
20 ml of ultrapure water) under magnetic stirring. Then, 
solvents were removed in a rotary evaporator at 37  °C 
(Buchi Labortechnik AG, Flawil, Switzerland) up to a 
final volume of 10 ml. Nanocapsules were characterized 
by their size, polydispersity index, zeta potential, colloi-
dal stability and morphology. Changes in physicochemi-
cal properties over time under specific conditions were 
measured using a Zetasizer Nano ZS® (Malvern Instru-
ments, Malvern, UK). Particle size distribution and 
morphology were evaluated by transmission electron 
microscopy (TEM) using a JEOL JEM-2010 microscope 
(Tokyo, Japan). DiD alone (DiD-loaded NCs) or in com-
bination with docetaxel (Molecular Probes-Invitrogen, 
USA) (DiD-DCX-loaded NCs) were associated to the 
nanocapsules by incorporating them into the oily phase. 
The nanocapsules were recovered by ultracentrifugation. 
The concentration of DiD and docetaxel (274 μg/mL and 
25 μM respectively) was quantified through UV spectro-
photometry at λ = 646 nm and high-performance liquid 
chromatography (HPLC), respectively.
Development and characterization of a 3D model 
mimicking a metastatic lymph node
A co-culture of A549 lung tumor cells and Jurkat E6.1 
lymphocytes was developed in 3D scaffolds (Insert™ PS 
3D Biotek LCC, North Brunswick, NJ). 50 μl of a cell sus-
pension at a concentration of 3 ×  105 of each cell type 
(A549 cells and Jurkat E6.1 lymphocytes) was added 
dropwise on the surface of the scaffolds. Jurkat cells were 
previously labeled with Vybrant DiI cell-labeling solution 
(Thermo Fisher Scientific, Spain) following the manu-
facture’s protocol. Co-cultures were incubated for 6  h 
before adding 450 μl of fresh culture medium. Cells were 
allowed to grow for 48 h and monitored using an inverted 
light microscope.
Scanning electron microscopy (SEM) was performed 
in order to characterize the model and identify the for-
mation of 3D cellular structures. Scaffolds were fixed 
in 4  % paraformaldehyde and washed extensively with 
phosphate buffer saline (PBS) and water. Samples were 
mounted on specimen holders (Ted Pella Inc., PELCO®) 
and dried at room temperature. Prior to examination, 
each sample was coated with gold and visualized using a 
Carl Zeiss Ultra Plus Scanning Electron Microscope.
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Confocal Laser Scanning Microscopy (CLSM) allowed 
the identification of both cell populations. 3D cell co-cul-
tures growing into Insert™ PS scaffolds were rinsed with 
PBS. Cell nuclei were stained with Hoechst 33342 (Invit-
rogen) (1:1000). Image z-stacks were captured with a 20× 
objective using a confocal microscope (TCS SP5, Leica 
Microsystems GmbH, Heidelberg), with a scanning speed 
of 400 Hz and image resolution of 1024 × 1024 pixels.
Interaction of PGA‑PEG NCs with cancer cells in 2D 
monolayers
Cells were seeded on coverslips in a multiwell-24 plate 
(Thermo Fisher Scientific) at 7.5 × 104 cells/well in 10 % 
FBS supplemented medium. After 24 h, cells were incu-
bated with dilutions of DiD-loaded and DiD-DCX-loaded 
PGA-PEG NCs in cell culture medium at a fluorescent 
probe concentration of 0.5  μg/ml (in the case of DiD-
DCX-loaded PGA-PEG NCs, the concentration of doc-
etaxel was 25 nM). After 4 h of incubation, nanocapsules 
were removed by PBS washing and cells were fixed with 
4  % paraformaldehyde. Staining of the nuclei was per-
formed using DAPI (Life Technologies). Samples were 
analyzed by CLSM at 63× magnification.
Perfusion of PGA‑PEG NCs in a 3D model of a 
tumor‑infiltrated lymph node
Scaffolds were placed inside a bioreactor and coupled 
to an automatic syringe pump (New Era Pump Systems, 
Inc., NY, USA). DiD-loaded and DiD-DCX-loaded PGA-
PEG NCs diluted in fresh culture medium (0.5  μg/ml 
DiD and 50 nM DCX respectively) were perfused under 
dynamic conditions that mimic the lymphatic flow (2 μl/
min for 2 h). Scaffolds were then washed with cold PBS 
(10 μl/min for 1 h) and placed in fresh culture medium. 
After 48  h, cells were fixed with 4  %  paraformaldehyde 
and analyzed by CLSM at 20× magnification. In a sec-
ond subset of experiments, cells were recovered from 
the scaffolds by trypsinization and analyzed by FACS 
(fluorescent activated cell sorting). Also, 2D co-cultures 
were used as controls and collected for the analysis. Pel-
lets were rinsed with PBS, counted, and resuspended in 
500 μl of PBS–FBS 2 %. Then, tubes were placed on ice 
and analyzed within 2 h using a FACScan flow cytometer 
(BD Biosciences, Madrid, Spain), single-laser (488  nm) 
excitation and a LP670 filter. Results were analyzed using 
FlowJo Software (TreeStar Inc., Ashland, USA).
Cell cycle analysis
Cell cycle analysis was performed in the cells recovered 
from the 3D co-cultures (3D). Cells from 2D co-cultures 
(2D) were used as controls and collected for the analy-
sis. Cells were fixed in ice-cold ethanol, dropwise while 
vortexing, and then washed with PBS–FBS 2  %. Pellets 
were resuspended in PI (propidium iodide) staining solu-
tion and incubated for 30 min in the dark. A minimum 
of 10,000 events per condition was measured by flow 
cytometry using a FACScan flow cytometer (BD Bio-
sciences, Madrid, Spain). The analysis of the results was 
performed using FlowJo Software (TreeStar Inc., Ash-
land, USA).
Results
Preparation and characterization of PGA‑PEG NCs
PGA-PEG NCs, prepared by the solvent displacement 
technique [19, 20], exhibit interesting features that 
make them attractive as lymphatic drug delivery carriers 
(Table 1). They can be easily prepared, have a hydrophilic 
surface (PEG chains), and form homogeneous popula-
tions of spherical particles with a small size (116 ± 5 nm) 
and a negative zeta potential (−29 ± 5 mV).
For the preparation of fluorescent nanocapsules, 
DiD was successfully entrapped into the oily core (final 
loading 0.76 % w/w with respect to the total amount of 
oil). The resultant DiD-loaded nanocapsules were con-
veniently characterized, having a mean particle size of 
112  ±  12  nm, and a zeta potential of −38  ±  2  mV. In 
addition, fluorescent nanocapsules that co-encapsulate 
docetaxel (DiD- DCX-loaded PGA-PEG NCs) were 
successfully prepared without important changes in 
their physicochemical properties, having a mean size of 
109 ±  13  nm and a zeta potential of −39 ±  1  mV. The 
encapsulation efficiency for docetaxel was 52  ±  1 (%) 
providing a final drug concentration in the nanoparticle 
suspension of 25 μM.
Development of a 3D cell model mimicking a metastatic 
lymph node
Lung tumor cells and lymphocytes were cultured 
together in 3D polystyrene scaffolds and allowed to grow 
for up to 48 h. Cell growth was directly monitored under 
the optical microscope (Fig.  1a). Additionally, scanning 
electron microscopy (Fig. 1b) provided a visual evidence 
of the 3D internal structure of the co-culture, showing 
the fibers of the scaffold covered by clusters of cells. Fur-
thermore, using confocal microscopy we also confirmed 
that lymphocytes, previously stained with the stable cell 
tracer DiI [21], were successfully embedded in the 3D 
matrix (Fig. 1c, red signal).
PGA‑PEG NCs can interact with lung cancer cells 
and deliver their cargo
The ability of PGA-PEG NCs to interact with lung can-
cer cells was first assessed in conventional cell cultures of 
cancer cells (2D monolayers). As observed in Fig. 2a, DiD-
loaded PGA-PEG NCs were efficiently internalized by the 
tumor cells after 24 h of incubation, and evenly distributed 
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into the cell cytoplasm and perinuclear area (green signal). 
On the other hand, DiD-DCX-loaded PGA-PEG NCs were 
similarly internalized (green signal) and docetaxel deliv-
ered intracellularly, leading to a cytotoxic effect character-
ized by cell multinucleation and enlargement (Fig. 2b).
PGA‑PEG NCs can selectively interact with lung cancer cells 
in the 3D co‑culture cell model mimicking a metastatic 
lymph node
Next experiments were aimed to determine the poten-
tial of the nanocapsules to reach metastatic lung cancer 
cells in a selective fashion in our 3D model of a meta-
static lymph node, under dynamic conditions. The perfu-
sion flow rate of the nanocapsules was determined based 
on previous studies [22]. Indeed, this scenario definitely 
contributes to create realistic physiological barriers that 
hinder nanocapsules penetration into the cells. Nanocap-
sules perfused through the model should be able to inter-
act with cancer cells in a short time frame (in 2D cultures 
cells are exposed to drugs/nanocarriers for long incuba-
tion times). Additionally, nanocapsules should penetrate 
into the tumor mass and have a preference for cancer 
cells with respect to other cells of the microenvironment, 
in this case immune cells.
As observed in Fig.  3a, after perfusion of PGA-PEG 
NCs, fluorescence was detected around the cell nuclei in 
cells that were negative for DiI staining (i.e. tumor cells, 
as Jurkat lymphocytes were stained with DiI, red signal). 
Figure 3b shows a different z-stack section with a higher 
amount of lymphocytes, in which we can observe that 
green fluorescence does not co-localize with the red sig-
nal of DiI. In order to confirm these results, and to obtain 
quantitative data, we performed a subsequent analysis by 
flow cytometry shown in Fig.  3c. Both cell populations, 
tumor cells and lymphocytes, were recovered from the 
3D co-culture and were identified separately by inde-
pendent gating of each population. Data indicate that 
30.9  % of the cells were positive for DiD fluorescence, 
Table 1 Physicochemical properties of PGA-PEG NCs
Values are given as mean ± S.D, n = 3
a PI polydispersity index, b EE encapsulation Efficiency, c DCX docetaxel, d Yes stands for stable nanocapsules at the conditions of study, e 4 °C during 7 months, f 37 °C 
for 4 h in cell culture medium, g transmission electron microscopy micrograph 
Physicochemical properties EE [%]b Stabilityd Morphologyg
PGA‑PEG NCs Size [nm] P.Ia ζ Potential [mV] DiD DCXc Storagee Cell mediaf
Blank 116 ± 5 0.1 −29 ± 5 – – Yes Yes
DiD‑loaded 112 ± 12 0.1 −38 ± 2 56 ± 3 – Yes Yes 100 nm
DiD‑DCX‑loaded 109 ± 13 0.2 −39 ± 1 52 ± 1 48 ± 8 Yes Yes
Fig. 1 Characterization of a 3D cell model mimicking a metastatic lymph node. a A549 lung cancer cells and Jurkat lymphocytes were co‑cultured 
in polystyrene scaffolds and observed as a tumor‑like mass by optical microscopy. b Internal structure and architecture of the 3D co‑culture was 
verified by scanning electron microscopy (SEM) at 500× magnification. c The presence of lymphocytes embedded in the culture (red: lymphocytes 
stained with DiI) was confirmed by confocal laser scanning microscopy (CLSM). Cell nuclei of both tumor cells and lymphocytes were counter‑
stained with DAPI, blue channel
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Fig. 2 Cellular uptake studies in A549 lung adenocarcinoma cells growing in 2D monolayers. Cells were incubated for 24 h with a DiD‑loaded and 
b DiD‑DCX‑loaded PGA‑PEG NCs (green channel). Cell nuclei were counterstained with DAPI (blue channel). Accumulation of nanocapsules carrying 
DiD and docetaxel in the cells produced a cytotoxic effect characterized by nuclei fragmentation. Insets show the boxed areas at a higher magnifica‑
tion
Fig. 3 Interaction of PGA‑PEG NCs with lung cancer cells in a 3D model of a metastatic lymph node. Scaffolds were perfused with DiD‑loaded 
PGA‑PEG NCs (green channel). a, b Confocal microscopy z‑stacks with a different number of lymphocytes (red channel) showing accumulation of 
the fluorescent nanocapsules in cells that were negative for the DiI staining (lymphocytes, red channel). Cell nuclei of cancer cells and lymphocytes 
were counterstained with DAPI (blue channel). c Graphical representation of the uptake of DiD‑loaded PGA‑PEG NCs after perfusion in the 3D 
co‑culture and incubation in 2D co‑cultures monolayers, determined by FACS. Populations were gated separately to determine the percentage (%) 
of cancer cells (A549) and lymphocytes (Jurkat) that were positive for DiD (DiD‑loaded PGA‑PEG NCs). Bars represent the mean ± SD (n = 3). NCs 
nanocapsules
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the majority of which were tumor cells (30.88  %), while 
just 0.02 % of DiD-positive cells were identified as lym-
phocytes. 2D co-cultures, in which the interaction and 
internalization of PGA-PEG NCs takes place under static 
conditions, were also analyzed as controls and presented 
a similar fluorescent pattern. In this case, 65.82 % of the 
cells were positive for the DiD fluorescence. This percent-
age corresponded mostly to tumor cells (65.81 %) in com-
parison with the lymphocytes (0.01 %).
With respect to the perfusion of DiD-DCX-loaded 
PGA-PEG NCs, in this case and oppositely to what we 
observed in 2D, a cytotoxic effect was not appreciated 
when the cells were visualized by confocal microscopy, 
since cell morphology and nuclei were not affected (data 
not shown). Experiments to understand these differences 
in the activity of the nanocapsules were subsequently 
performed, and are disclosed in the next section.
Cell cycle analysis
Considering the mechanism of action of docetaxel, an 
antimitotic agent, and the absence of a cytotoxic effect 
in our 3D model, we decided to analyze the cell-cycle 
phase distribution of cancer cells (G0/G1, S and G2/M). 
Results show that the 3D model is characterized for the 
presence of a higher percentage of cells in phase G0/G1 
than in G2/M, therefore suggesting a cell-cycle arrest 
(Fig. 4). This distribution can be attributed to the three-
dimensional organization since cells recovered from the 
2D co-cultures, analyzed as a control, show a significative 
smaller number of cancer cells under G0/G1 arrest.
Discussion
PGA-PEG NCs, i.e. PGA-PEG coated oil in water nanoe-
mulsions stabilized with surfactants, were successfully 
engineered with a mean size close to 100  nm, a round 
shape, a negative zeta potential and a hydrophilic surface. 
These characteristics are important as they are known to 
enhance the blood circulation time, the penetration rates 
into the tumor mass and the migration through the inter-
stitial space towards the lymphatics [9, 11, 23]. Recent 
results show that they have an enormous potential for 
the treatment of metastatic lung cancer since they can 
efficiently reach regional lymph nodes after subcutane-
ous administration to mice [19]. As a step forward, in this 
work the objective was to elucidate the capacity of PGA-
PEG NCs to efficiently interact with cancer cells, while 
avoiding a non-specific interaction with the immune cells.
For nanoparticle tracking, the fluorescent probe DiD 
was successfully entrapped into PGA-PEG NCs. Nano-
capsules were stable, since they preserve their physico-
chemical properties during storage for up to 7  months, 
and in cell culture medium at 37 °C for 4 h. Additionally, 
DiD was not prematurely released from the formulation 
in the tested conditions. The gold standard treatment in 
lung cancer, the hydrophobic drug docetaxel, was also 
incorporated in the formulation with high association 
efficiency and reaching a concentration of 25 μM in the 
nanoparticle suspension. The incorporation of DiD and 
docetaxel did not have a significant effect on the size and 
surface properties of the nanocapsules, with respect to 
blank PGA-PEG NCs.
The capacity of PGA-PEG NCs to enter the cancer 
cells and release their cargo was first explored in con-
ventional 2D cultures of lung cancer cells. As expected, 
results showed that PGA-PEG NCs accumulated into the 
cell cytoplasm and were evenly distributed in the culture. 
Due to their small size, nanoparticles could probably 
enter the cells by different mechanisms such as endocy-
tosis and pinocytosis [24]. Moreover, the ability of PGA-
PEG NCs to release the associated drug intracellularly 
was proved on view of the cytotoxic effect exerted after 
their effective internalization into lung cancer cells. How-
ever, even if the interaction of nanocarriers with cancer 
cells and therapeutic efficiency have been traditionally 
performed in 2D cell monolayers, they poorly represent 
the in vivo situation [25, 26].
Consequently, we aimed next to evaluate if PGA-PEG 
NCs could interact specifically with disseminated tumor 
cells in a model more representative of the metastatic situ-
ation. 3D platforms, i.e. spheroids and hydrogels, have been 
proposed for the evaluation of the capacity of nanoparticles 
to diffuse into tumors and interact with cancer cells [27, 
28]. However, these models do not consider the dynamic 
flow. This is particularly relevant since cells in tissues are 
naturally subjected to fluid flow, which influence cellular 
functions, and crucially determines the diffusion of the 
nanocarriers through the tumor, limiting their contact and 
interaction with the cells [29, 30]. We have designed and 
Fig. 4 Flow cytometry analysis of the cell cycle distribution in the 3D 
co‑culture model of a metastatic lymph node, and in 2D co‑cultures 
monolayers. The graph shows the percentage of cells in each phase 
of the cell cycle and apoptotic cells. Bars represent the mean ± SD 
(n = 3). ***p value <0.001 *p value <0.05
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characterized a 3D model that addresses this specific limi-
tation and enable the perfusion of the nanocarriers under 
dynamic controlled conditions. An additional important 
feature of the 3D platform developed in this work relies on 
the incorporation of lymphocytes, in an attempt to repro-
duce the physiological environment of a metastatic lymph 
node. After a series of experiments intended to adjust the 
cell ratio and the seeding conditions, lung tumor cells and 
lymphocytes were successfully co-cultured in a porous 3D 
matrix. This complex structure composed by polystyrene 
and organized in four layers of polymer fibers with open 
interconnected pores provided cells with the appropriate 
support in a physiological environment, allowing exchange 
of nutrients and cell metabolism waste.
The results obtained after perfusion of DiD-loaded 
PGA-PEG NCs in the 3D model showed a selective 
interaction with the tumor cells. Indeed, fluorescent 
nanocapsules were observed around the cell nuclei of 
cancer cells (negative staining for DiI) under the confo-
cal microscope. Additionally, FACS experiments allowed 
gathering quantitative data supporting this observation. 
The selective internalization of PGA-PEG NCs by cancer 
cells could be explained considering that biodegradable 
nanostructures are typically internalized by endocytosis 
[24] and lymphocytes are known as non-phagocytic cells 
[31]. Also, the hydrophilic characteristics conferred to 
the nanosystems by the neutral ligand poly (ethylene gly-
col) (PEG) might help preventing the interaction with the 
immune cells [32]. In addition, the internalization could 
have been favored by the known avidity of cancer cells 
for PGA as well, as previously described [33]. Due to the 
structure of the nanocapsules and the methodology of 
preparation, PGA is partially disposed onto the surface of 
the nanocapsules, and therefore accessible to cancer cells.
The internalization of the nanocapsules after perfu-
sion in 3D co-cultures under dynamic conditions, was 
compared with that determined in 2D co-cultures after 
incubation under static conditions. Important differences 
were observed, as the percentage of positive DiD cells 
moved from 65 % in 2D co-cultures to 30 % in the 3D co-
cultures. The reason could be that, whereas nanocapsules 
are delivered in a bulk solution on top of the 2D cultures, 
their access to the cells in 3D cultures might be hindered 
by architectural and physiological factors [25], as well as 
by a limited residence time over the cell surface. Despite 
of these facts, an important percentage of cells were posi-
tive after perfusion, suggesting an effective internaliza-
tion process of the nanocapsules even when cells are in a 
dynamic 3D environment.
Regarding their potential in anticancer therapy, we 
confirmed that PGA-PEG NCs can efficiently entrap the 
hydrophobic drug docetaxel and release it intracellu-
larly in an active form, as confirmed in conventional 2D 
monolayers confocal images after exposure to DiD-DCX-
loaded PGA-PEG NCs, and in line with previous works 
in the field [34–36]. Interestingly, this antitumoral effect 
was not observed after perfusion of DiD-DCX-loaded 
PGA-PEG NCs through the 3D co-cultures. This lack of 
effect as compared to the significant response observed 
in the 2D model could be attributed to the mechanism of 
action of docetaxel. Indeed, docetaxel is known to bind 
and stabilize the microtubule network in proliferating 
cells thus preventing cell division [37]. However it has no 
effect on cells that are in the resting phase, which is the 
cell cycle status of cancer cells in the developed 3D model 
of a metastatic lymph node. In fact, when cells were cul-
tured in 3D, the percentage of cells in phase GO/G1 was 
significantly increased (65 %) compared to cells cultured 
in 2D (30 %). This result is particularly interesting since it 
has been described that lymph node-resident metastatic 
cells often enter on a dormant state, and that the immune 
system has been proposed as a key player on the induc-
tion or maintenance of cell dormancy [38, 39]. Cancer 
dormant cells resident in the lymph nodes might eventu-
ally be re-activated and end up producing distant metas-
tasis due to microenvironmental cues and other signals. 
Therefore, it seems important to deliver therapies that 
are specifically targeted to these dormant cells. Nano-
capsules are versatile systems in which different types 
of drugs, from small molecular weight anticancer drugs 
to high molecular weight hydrophilic biomolecules (i.e. 
gene therapies and proteins) can be associated [19, 40, 
41], and can hold potential for this particular application.
Our results highlight the importance of developing 
appropriate anti-cancer therapies particularly addressed 
to metastatic cancer cells, and in parallel, suitable in vitro 
models that allows understanding and validating the 
efficacy of the proposed therapies. Indeed, we believe 
that the availability of in vitro models that represent the 
metastatic situation could significantly contribute to the 
development of novel antitumoral therapies addressed to 
interfere cancer dissemination.
Conclusions
We have prepared fluorescent PGA-PEG NCs with phys-
icochemical properties that make them attractive for 
targeting the lymph nodes and delivery of anticancer 
therapeutics. We have proved a selective interaction of 
PGA-PEG NCs with cancer cells in presence of immune 
cells, and hence the potential for the treatment of can-
cer that undergoes lymphatic dissemination. For that, we 
have successfully developed a 3D model of a metastatic 
lymph node representative of the physiological situation, 
which could additionally be of utility for the screening 
of novel therapeutic strategies specifically addressed to 
tackle metastatic dormant cells.
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